Patients monitoring during treatment with Dimethyl fumarate (ORP-23)
Dimethyl Fumarate (DMF) is a methyl ester of fumaric acid (chemical formula C6H8O4) that is hydrolyzed in the small intestine to the active metabolite monomethyl fumarate, approved for the treatment of RMS, and moderate to severe Psoriasis. In addition to relative frequencies, we also examined the a...
Main Author: | Ali Yousefi Pour |
---|---|
Format: | Article |
Language: | English |
Published: |
Iran University of Medical Sciences
2023-01-01
|
Series: | Neurology Letters |
Subjects: | |
Online Access: | https://www.neurologyletters.com/article_184228_d41d8cd98f00b204e9800998ecf8427e.pdf |
Similar Items
-
Dimethyl fumarate reduces inflammation in chronic active multiple sclerosis lesions
by: Zinger, Nicole, et al.
Published: (2023) -
Utilization of dimethyl fumarate and related molecules for treatment of multiple sclerosis, cancer, and other diseases
by: Azzam Maghazachi, et al.
Published: (2016-07-01) -
Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate
by: Dipen Sangurdekar, et al.
Published: (2019-11-01) -
A Bibliometric Evaluation of the Top 100 Cited Dimethyl Fumarate Articles
by: Francisco Javier García-Fernández, et al.
Published: (2021-02-01) -
USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS
by: V. R. Mkrtchyan, et al.
Published: (2016-12-01)